Search
Tyrothricin
go.drugbank.com/drugs/DB13503ApprovedWithdrawnTyrothricin is an antibiotic peptide complex produced and extracted from the aerobic Gram-positive bacillus Brevibacillus parabrevis [L4019, L4021, A32851] which was previously categorized as Bacillus … This complex is a mixture comprised of 60% tyrocidine cationic cyclic decapeptides (consisting largely of the six predominant tyrocidines, TrcA/A1, TrcB/B1, TrcC/C1, and other more minor contributors)
Mixtures: Tyrothricin "Provita" comp. - LutschtablettenDydrogesterone
go.drugbank.com/drugs/DB00378ApprovedInvestigationalWithdrawnUnlike many other progestational compounds, dydrogesterone produces no increase in temperature and does not inhibit ovulation.
Emapalumab
go.drugbank.com/drugs/DB14724ApprovedInvestigationalEmapalumab development was sponsored by NovImmune SA, further developed by Sobi and FDA approved on November 20, 2018.
Choline C 11
go.drugbank.com/drugs/DB09277Approved[A32041] It was developed by MCPRF and FDA first approved in September 2012.
Sodium cellulose phosphate
go.drugbank.com/drugs/DB06776Approved[A31694] This compound is an ion-exchange resin that can not be absorbed by the body. However, it can be used to restore normal intestinal calcium absorption.
Categories: Compounds used in a research, industrial, or household settingEconazole
go.drugbank.com/drugs/DB01127ApprovedIt is used topically in dermatomycoses also orally and parenterally.
Mixtures: TRILON-E CREAMN-(2-Aminoethyl)-1-aziridineethanamine
go.drugbank.com/drugs/DB15643ExperimentalFirst described in the literature in 2004, N-(2-Aminoethyl)-1-aziridineethanamine is an experimental angiotensin converting enzyme 2 inhibitor investigated for its use in treating cardiovascular disease
Categories: Agents Acting on the Renin-Angiotensin SystemSynonyms: N-(2-((2-Aminoethyl)amino)ethyl)aziridine, N-(2-aminoethyl)-1 aziridine-ethanamineRepotrectinib
go.drugbank.com/drugs/DB16826ApprovedInvestigationalThis approval is based on favorable results from the TRIDENT-1 study, where the objective response rate was 79% in TKI-naive patients and 38% in TKI-pretreated patients respectively.[L48741] … Repotrectinib is a next-generation tyrosine kinase inhibitor (TKI) specifically designed to address resistance in the treatment of non-small cell lung cancer (NSCLC), specifically due to mutations in the
Sevabertinib
go.drugbank.com/drugs/DB21667ApprovedInvestigational[L54638] It was granted accelerated approval by the FDA on November 19th, 2025.[L54608]
Propylthiouracil
go.drugbank.com/drugs/DB00550ApprovedIt is used in the treatment of hyperthyroidism. (From Martindale, The Extra Pharmacopeoia, 30th ed, p534)